Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years’ experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and fully owned subsidiary of Novozymes A/S.
Dr Dave MeadDirector, IP & Business Development
Dr Alberto MartinezClinical Development Director
Mr Jonas MøllerGlobal Head of Marketing & Corporate Strategy
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.
Dr STEVE McCONCHIECEO
At Arcinova, we are focused on Process Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covering drug candidates in Development and launched to the Market. We are trusted partners for our customers, supporting their development and delivery programmes for new medicines in a timely and cost effective manner to sustainably improve the health and wellbeing of society. Our mission at Arcinova is to deliver best in class technology services in the fields of contract research, development and small scale manufacturing to maximise effectiveness whilst minimising risk and overall cost.
Dr Mark ChadwickHead of Business Development
Biotech & Money
Biotech and Money is a growing influential community of senior life science decision makers. We are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. We are determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. We do this by channelling our efforts into identifying and sharing genuine thought leadership, executive insight and market intelligence. We disseminate this knowledge through an in depth bimonthly publication; Drugs & Dealers, through our web portal and critically through world class conferences and events that break the mould with innovative formats, networking and business development opportunities. We bring deals to life.
Mr Matthew PullanSenior Vice President
Cello Health Consulting
Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success, and enables us to provide a greater depth and breadth of services to help support your critical decision making.
Mr Adrian WalfordVice President, Business Development
CIMYM BioSciences was established to develop oncology and immunological therapeutics. At CIMYM we believe passionately that drug development can only be successful if it is patient centred…’Begin with the patient in mind'. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care. CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.